Using biofluid markers to detect Alzheimer's disease early in Colombia
Official title: IMPLEMENTATION OF BIOFLUID MARKERS FOR EARLY DETECTION OF ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES IN COLOMBIA
Funded at University of Antioquia · NIH-11087256 · Data updated 2026-11-12
This study is looking to make it easier to spot Alzheimer's and similar brain diseases by using special markers found in blood samples, and it's designed for people in Colombia to help doctors better understand and treat these conditions.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Antioquia NIH-funded |
| Lab location | 1 site (Medellin, Colombia) |
| Project start | September 30, 2022 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $26,500 |
| NIH project number | 3R21AG079574-01S1 |
| Project ID | NIH-11087256 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals in Colombia who are at risk for Alzheimer's disease or exhibit early symptoms of neurodegenerative conditions.
✕Less likely to help
Patients outside of Colombia or those without risk factors for Alzheimer's disease may not benefit from this research.
What this research studies
This research focuses on improving the detection of Alzheimer's disease and other neurodegenerative diseases by utilizing biofluid markers in Colombia. The project aims to integrate these markers into routine clinical practice and research, enhancing the capabilities of the Neuroscience Group at the University of Antioquia. By analyzing serum samples using advanced technology, the research will validate the effectiveness of these biomarkers in identifying patients at risk for Alzheimer's disease. This initiative is particularly significant given the unique genetic diversity of the Colombian population, which may provide valuable insights into the disease.
Why it matters
Potential benefit: If successful, this research could lead to earlier detection and better management of Alzheimer's disease, improving patient outcomes.
How similar studies have gone: Previous research has shown promise in using biofluid markers for early detection of Alzheimer's disease, indicating that this approach has potential for success.
Where this research is happening
-
University of Antioquia
Medellin, Colombia Active
Researchers
- Principal investigator: Cardona-Gómez, Gloria Patricia — University of Antioquia
- Study coordinator: Cardona-Gómez, Gloria Patricia
Related research
Other NIH-funded projects on the same topics.
-
Understanding resilience to Alzheimer's disease in Colombian families with genetic mutations
This study is looking at how specific genetic changes linked to early-onset Alzheimer's disease impact memory and thinking skills in people from Colombia, especially those with these mutations and their family members, to find out what helps some people stay mentally sharp despite the disease.
-
Using blood markers to detect Alzheimer's disease early in Colombia
This study is working on finding new blood tests to help spot Alzheimer's disease and other brain disorders early, so that people in Colombia can get better care and treatment sooner.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.